missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human NT5C3B Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (87%), Rat (87%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-63399 (PA5-63399. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Specifically hydrolyzes 7-methylguanosine monophosphate (m(7)GMP) to 7-methylguanosine and inorganic phosphate (PubMed:23223233, PubMed:24603684). The specific activity for m(7)GMP may protect cells against undesired salvage of m(7)GMP and its incorporation into nucleic acids (PubMed:23223233). Also has weak activity for CMP (PubMed:23223233, PubMed:24603684). UMP and purine nucleotides are poor substrates (PubMed:23223233). [UniProt]
Specifications
Specifications
| Accession Number | Q969T7 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 115024 |
| Name | Human NT5C3B Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2610037D24Rik; 5'-nucleotidase, cytosolic IIIB; 5'-nucleotidase, cytosolic III-like; 7-methylguanosine nucleotidase; 7-methylguanosine phosphate-specific 5'-nucleotidase; AI841843; C330027I04Rik; cN-IIIB; cN-III-like protein; Cytosolic 5'-nucleotidase 3 B; cytosolic 5'-nucleotidase III-like protein; cytosolic 5-nucleotidase III-like protein-like; N(7)-methylguanylate 5'-phosphatase; Nt5c3b; Nt5c3l |
| Common Name | NT5C3B |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction